LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 1.78 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 1.75▼ 1.8150-Day Range 1.75▼ 2.6152-Week Range 0.82▼ 3Volume1.12 million shsAverage Volume2.00 million shsMarket Capitalization£7.39 millionP/E RatioN/ADividend Yield0.77%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get ImmuPharma alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About ImmuPharma Stock (LON:IMM)ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.Read More IMM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMM Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comImmuPharma (LON:IMM) Stock Passes Above 200-Day Moving Average of $1.90May 29, 2024 | lse.co.uk5x Long Qqq Share ChatJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 26, 2024 | lse.co.ukHsbc Bk.24 Share ChatMay 8, 2024 | msn.comInvestigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyMay 8, 2024 | msn.comLooking for top FTSE 100 value shares? Here’s one I’d buy without hesitationApril 2, 2024 | lse.co.ukImmupharma jumps amid new IP strategy for P140 technology platformMarch 25, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 15, 2024 | msn.comSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 8, 2024 | finance.yahoo.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsFebruary 24, 2024 | morningstar.comImmuPharma PLC IMMFebruary 21, 2024 | lse.co.ukUK government borrowing surplus rises in January from prior yearJanuary 17, 2024 | ca.finance.yahoo.comImmuPharma PLC (25I.SG)December 19, 2023 | lse.co.ukEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | marketwatch.comImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 21, 2023 | lse.co.ukImmuPharma agrees 12 month extension to Incanthera warrant instrumentSee More Headlines Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/30/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CUSIPN/A CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-159.35% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.03 Sales & Book Value Annual Sales£94,819.00 Price / Sales77.96 Cash FlowGBX 0.09 per share Price / Cash Flow20.50 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares416,440,000Free FloatN/AMarket Cap£7.39 million OptionableNot Optionable Beta1.46 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Timothy Paul McCarthy XIV (Age 68)FCCA, M.B.A., MBA, Chairman & CEO Comp: $106.5kDr. Timothy Gary Franklin M.B.A. (Age 60)Ph.D., COO & Director Comp: $92.5kMs. Lisa Baderoon (Age 58)Head of Investor Relations & Non Executive Director Comp: $48kDr. Jean-Marie Geiger PharmDMD, Head of Clinical DevelopmentDr. Laura Mauran-Ambrosino Ph.D.Chief Scientific Officer of ImmuPharma BiotechMs. Lara E. Sucheston-CampbellHead of Clinical & Medical AffairsDr. Sébastien R. Goudreau Ph.D. (Age 43)CEO of ImmuPharma Biotec & Director More ExecutivesKey CompetitorsC4X DiscoveryLON:C4XD4D pharmaLON:DDDDArecor TherapeuticsLON:ARECOxford BioDynamicsLON:OBDOndine BiomedicalLON:OBIView All Competitors IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 1.67 at the beginning of 2024. Since then, IMM shares have increased by 6.4% and is now trading at GBX 1.78. View the best growth stocks for 2024 here. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) issued its earnings results on Wednesday, September, 30th. The company reported ($1.69) EPS for the quarter. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), MOTIF BIO PLC/S (MTFB), Aminex (AEX), Legendary Investments (LEG), Richland Resources Ltd (RLD.L) (RLD), Sound Energy (SOU) and Thor Energy (THR). This page (LON:IMM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMM Stock Alerts